The Substance Abuse and Mental Health Services Administration yesterday issued guidance for health care and addiction professionals using methadone, naltrexone or buprenorphine to treat patients with opioid use disorder. Mandated by the Comprehensive Addiction and Recovery Act, the guidance offers appropriate prescribing practices and strategies for supporting patients. It also educates patients, families and the general public about the medications. “We know that people can and do recover from opioid use disorders when they receive appropriate treatment, and medication-assisted treatment’s success in treating opioid use disorders is well documented,” said Elinore McCance-Katz, M.D., assistant secretary for mental health and substance use at the Department of Health and Human Services. For an AHA toolkit and other resources to help hospitals and health systems tackle the opioid crisis, visit www.aha.org/opioidtoolkit.

Related News Articles

Headline
Oct. 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired tablets, capsules, patches and…
Headline
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from…
Headline
As the House Energy and Commerce Committee works to reauthorize key programs within the Substance Use-Disorder Prevention that Promotes Opioid Recovery and…
Headline
While counseling and other services are an important part of a comprehensive treatment plan for opioid use disorder, the provision of medication should not be…
Headline
AHA today launched an updated Opioid Stewardship Hub, featuring the latest tools and resources to help hospitals and health systems address the opioid epidemic…
Headline
The Food and Drug Administration last week required certain labeling updates for opioid pain medicines in an effort to reduce unnecessary prescribing and…